These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 28657968)
1. Urine tenofovir and emtricitabine concentrations provide biomarker for exposure to HIV preexposure prophylaxis. Haaland RE; Martin A; Holder A; Fountain JJ; Hall L; Pescatore NA; Heeke S; Kelley CF AIDS; 2017 Jul; 31(11):1647-1650. PubMed ID: 28657968 [No Abstract] [Full Text] [Related]
2. Preexposure Prophylaxis with Tenofovir/Emtricitabine Prevents HIV Infection In Men who Have Unprotected Anal Intercourse. Ebell MH Am Fam Physician; 2016 Mar; 93(6):520. PubMed ID: 26977839 [No Abstract] [Full Text] [Related]
3. Urine assay for tenofovir to monitor adherence in real time to tenofovir disoproxil fumarate/emtricitabine as pre-exposure prophylaxis. Koenig HC; Mounzer K; Daughtridge GW; Sloan CE; Lalley-Chareczko L; Moorthy GS; Conyngham SC; Zuppa AF; Montaner LJ; Tebas P HIV Med; 2017 Jul; 18(6):412-418. PubMed ID: 28444867 [TBL] [Abstract][Full Text] [Related]
4. Risks and benefits HIV preexposure prophylaxis with tenofovir/emtricitabine in an older male with comorbidities. Girometti N; Jones R; Levy J; McCormack S; Sullivan A; Barber TJ AIDS; 2016 Aug; 30(13):2131-3. PubMed ID: 27219131 [TBL] [Abstract][Full Text] [Related]
5. Update on HIV prevention and preexposure prophylaxis. Baker J; Rolls J JAAPA; 2020 Jun; 33(6):12-17. PubMed ID: 32384293 [TBL] [Abstract][Full Text] [Related]
6. Is sub-Saharan Africa ready for pre-exposure prophylaxis? Bernier A; Gapiya J; Sylla A; Anoma C; Somda M; Dah E; Aranda JF; Himmich H Lancet HIV; 2016 Apr; 3(4):e154-5. PubMed ID: 27036989 [No Abstract] [Full Text] [Related]
7. Decline in Bone Mass With Tenofovir Disoproxil Fumarate/Emtricitabine Is Associated With Hormonal Changes in the Absence of Renal Impairment When Used by HIV-Uninfected Adolescent Boys and Young Men for HIV Preexposure Prophylaxis. Havens PL; Stephensen CB; Van Loan MD; Schuster GU; Woodhouse LR; Flynn PM; Gordon CM; Pan CG; Rutledge B; Liu N; Wilson CM; Hazra R; Hosek SG; Anderson PL; Seifert SM; Kapogiannis BG; Mulligan K; Clin Infect Dis; 2017 Feb; 64(3):317-325. PubMed ID: 28013265 [TBL] [Abstract][Full Text] [Related]
8. Pre-exposure prophylaxis is effective at preventing HIV in high risk gay men, study shows. Mayor S BMJ; 2015 Sep; 351():h4860. PubMed ID: 26359448 [No Abstract] [Full Text] [Related]
9. Better late than never: PrEP in England. The Lancet Hiv Lancet HIV; 2017 Jan; 4(1):e1. PubMed ID: 28007341 [No Abstract] [Full Text] [Related]
10. Welcome to the preexposure prophylaxis revolution. Baeten J; McCormack S Curr Opin HIV AIDS; 2016 Jan; 11(1):1-2. PubMed ID: 26633637 [No Abstract] [Full Text] [Related]
11. UK PrEP decision re-ignites HIV activism. The Lancet Lancet; 2016 Apr; 387(10027):1484. PubMed ID: 27115959 [No Abstract] [Full Text] [Related]
12. Understanding Adherence to Daily and Intermittent Regimens of Oral HIV Pre-exposure Prophylaxis Among Men Who Have Sex with Men in Kenya. Mugo PM; Sanders EJ; Mutua G; van der Elst E; Anzala O; Barin B; Bangsberg DR; Priddy FH; Haberer JE AIDS Behav; 2015 May; 19(5):794-801. PubMed ID: 25432877 [TBL] [Abstract][Full Text] [Related]
13. Implementing preexposure prophylaxis among key populations: an opportunity for patient-centered services and management of hepatitis B. Larmarange J; Becquet V; Masumbuko JM; Nouaman M; Plazy M; Danel C; Eholié S AIDS; 2018 Mar; 32(6):829-830. PubMed ID: 29543655 [No Abstract] [Full Text] [Related]
14. Should we fear resistance from tenofovir/emtricitabine preexposure prophylaxis? Parikh UM; Mellors JW Curr Opin HIV AIDS; 2016 Jan; 11(1):49-55. PubMed ID: 26633640 [TBL] [Abstract][Full Text] [Related]
15. A case of M184V mutant human immunodeficiency virus in a patient using daily pre-exposure prophylaxis. Jewsbury S; Ward C Int J STD AIDS; 2020 Jan; 31(1):85-87. PubMed ID: 31801029 [No Abstract] [Full Text] [Related]
17. Acquisition of wild-type HIV-1 infection in a patient on pre-exposure prophylaxis with high intracellular concentrations of tenofovir diphosphate: a case report. Hoornenborg E; Prins M; Achterbergh RCA; Woittiez LR; Cornelissen M; Jurriaans S; Kootstra NA; Anderson PL; Reiss P; de Vries HJC; Prins JM; de Bree GJ; Lancet HIV; 2017 Nov; 4(11):e522-e528. PubMed ID: 28919303 [TBL] [Abstract][Full Text] [Related]
18. InterPrEP: internet-based pre-exposure prophylaxis with generic tenofovir disoproxil fumarate/emtrictabine in London - analysis of pharmacokinetics, safety and outcomes. Wang X; Nwokolo N; Korologou-Linden R; Hill A; Whitlock G; Day-Weber I; McClure MO; Boffito M HIV Med; 2018 Jan; 19(1):1-6. PubMed ID: 28657199 [TBL] [Abstract][Full Text] [Related]
19. Low Risk of Proximal Tubular Dysfunction Associated With Emtricitabine-Tenofovir Disoproxil Fumarate Preexposure Prophylaxis in Men and Women. Mugwanya K; Baeten J; Celum C; Donnell D; Nickolas T; Mugo N; Branch A; Tappero J; Kiarie J; Ronald A; Yin M; Wyatt C; J Infect Dis; 2016 Oct; 214(7):1050-7. PubMed ID: 27029778 [TBL] [Abstract][Full Text] [Related]
20. How to "PrEP" for HIV Prevention in Women. Ntim GJ; Kransdorf LN J Womens Health (Larchmt); 2017 Feb; 26(2):195-196. PubMed ID: 28140756 [No Abstract] [Full Text] [Related] [Next] [New Search]